Literature DB >> 20561645

Sacral neuromodulation in children with urinary and fecal incontinence: a multicenter, open label, randomized, crossover study.

M Haddad1, R Besson, D Aubert, P Ravasse, J Lemelle, A El Ghoneimi, J Moscovici, F Hameury, K Baumstarck-Barrau, G Hery, J M Guys.   

Abstract

PURPOSE: The clinical benefit of sacral neuromodulation is unclear due to the paucity of randomized trial data. The purpose of this study was to evaluate sacral neuromodulation for management of urinary and fecal incontinence in a pediatric population.
MATERIALS AND METHODS: This multicenter, open label, randomized, crossover study included children older than 5 years. After trial stimulation of the S3 root a neuromodulator (InterStim) was implanted on the S3 foramen. Clinical examinations, voiding and bowel diaries, and urodynamic and manometric evaluations were performed at the beginning (t1) and end (t2) of the first period, and at the beginning (t3) and end (t4) of the second period.
RESULTS: A total of 33 patients (24 boys) with a mean +/- SD age of 12.22 +/- 5.09 years were randomized. Etiologies were mainly of neurological origin. Incontinence was mixed urinary and fecal in 19 cases, urinary only in 9 and fecal only in 5. Cystometric bladder capacity increased during sacral neuromodulation (delta +24.27 ml vs -37.45 ml, p = 0.01). There was no significant change in other urodynamic or manometric parameters. Overall positive response rate was more than 75% for urinary (81%) and bowel (78%) function. Crossover analysis indicated that sacral neuromodulation is more effective than conservative treatment for both types of incontinence (p = 0.001).
CONCLUSIONS: In a pediatric population sacral neuromodulation is effective for bladder and bowel dysfunction and should be considered before irreversible surgery. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20561645     DOI: 10.1016/j.juro.2010.03.054

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  How does sacral modulation work best? Placement and programming techniques to maximize efficacy.

Authors:  Bastian Amend; Mahmoud Khalil; Thomas M Kessler; Karl-Dietrich Sievert
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

Review 2.  [The future of invasive neuromodulation: new techniques and expanded indications].

Authors:  A van Ophoven; J Pannek
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 3.  Updates in the management of the overactive bladder in patients with myelomeningocele.

Authors:  Gregory E Dean; Christopher Long
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

4.  Incontinence. Pediatric sacral neuromodulation for refractory incontinence.

Authors:  Janelle A Fox; Yuri E Reinberg
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

5.  Sacral neuromodulation in congenital lumbo-sacral and traumatic spinal cord defects with neurogenic lower urinary tract symptoms: a single-center experience in children and adolescents.

Authors:  Farzaneh Sharifiaghdas
Journal:  World J Urol       Date:  2019-03-12       Impact factor: 4.226

Review 6.  What Is New in Neuromodulation?

Authors:  Courtenay K Moore; Jessica J Rueb; Samir Derisavifard
Journal:  Curr Urol Rep       Date:  2019-08-07       Impact factor: 3.092

Review 7.  Preventing kidney injury in children with neurogenic bladder dysfunction.

Authors:  Faezeh Javadi Larijani; Mastaneh Moghtaderi; Nilofar Hajizadeh; Farahnak Assadi
Journal:  Int J Prev Med       Date:  2013-12

8.  Comparison of antegrade continence enema treatment and sacral nerve stimulation for children with severe functional constipation and fecal incontinence.

Authors:  Mana H Vriesman; Lyon Wang; Candice Park; Karen A Diefenbach; Marc A Levitt; Richard J Wood; Seth A Alpert; Marc A Benninga; Karla Vaz; Desale Yacob; Carlo Di Lorenzo; Peter L Lu
Journal:  Neurogastroenterol Motil       Date:  2020-02-03       Impact factor: 3.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.